NFL Biosciences will present its results at the SRNT congress – 02/13/2024 at 6:17 p.m.

(AOF) – NFL Biosciences announces that it has been selected by the SRNT (Society for Research on Nicotine & Tobacco) to present the results of the Precesto study at the international congress of this world-leading scientific society in the fight against Smoking , which will be held in Edinburgh, Scotland from March 20-23. Conducted in 2023 on 34 smokers who did not wish to quit smoking, the study demonstrated the effectiveness of the drug candidate NFL-101 in reducing the satisfaction of smoking compared to a placebo.


Learn more about the Pharmacy sector

Oncology, priority of pharmaceutical giants

Sanofi’s stock market disappointment recorded at the end of October 2023 underlines the new direction for the group, which has now set oncology as its number 1 priority. Efforts in this segment, where therapies are advancing the fastest, notably involve investments in R&D which weigh on profitability. Sanofi therefore announced a drop in its earnings per share in 2024 and the abandonment of its objective of an operating margin of 32% in 2025. Merck has just unveiled a new alliance. It will pay up to $22 billion to the Japanese group Daiichi Sankyo as part of a partnership on experimental cancer treatments. While some experts estimate that the United States represents nearly half of global oncology spending (drugs and treatments), or $196 billion in 2022, Chinese spending in this area has more than doubled in five years, going from 5 to 11.8 billion dollars.

Source link -86